At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 194 enrolled
Drug / intervention
Chondroitin sulfate +1 moredrug
Likely dose
Chondroitin sulfate 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI
In Brief
A Phase 3 clinical trial evaluating Chondroitin sulfate and Celecoxib for Knee Osteoarthritis. Completed, enrolled 194 participants across 5 sites.
Detailed Summary
The main purpose of this study is to compare the cartilage volume loss at the Baseline visit and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Osteoarthritis
CountriesCanada
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionSep 2014
Study CompletionOct 2014
TodayJul 2026
First PostedMay 16, 2011
Enrollment StartJun 1, 2011
Primary CompletionSep 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.1 years ago
Interventions
Chondroitin sulfatedrug
Chondroitin sulphate 1200 mg/day, 24 months treatment period
Celecoxibdrug
Celecoxib 200 mg/day, 24 months treatment period